HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC

By Michael B. Atkins, MD - Last Updated: February 18, 2023

Michael B. Atkins, MD, of the Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the phase 2 HCRN GU16-260 study and what the data tell us for immunotherapy applicability in favorable-risk patients.

Post Tags:ASCO GU 2023-Renal Cell Carcinoma
Advertisement
Advertisement